Supernus Pharmaceuticals (SUPN) Amortization of Deferred Charges (2011 - 2023)

Supernus Pharmaceuticals (SUPN) has 13 years of Amortization of Deferred Charges data on file, last reported at $532000.0 in Q1 2023.

• Amortization of Deferred Charges for Q1 2023 came in at $532000.0, up 1.14% year-over-year; the trailing twelve-month figure through Dec 2023 was $532000.0 (down 74.48% YoY), and the FY2023 annual result was $532000.0, down 74.81% from the prior year.
• Amortization of Deferred Charges steadied at $532000.0 in Q1 2023 per SUPN's latest filing, from $530000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $4.5 million in Q4 2021 and troughed at $500000.0 in Q2 2022.
• A 5-year average of $3.1 million and a median of $4.0 million in 2019 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2019 and 2022: Amortization of Deferred Charges jumped 528.76% in 2019, then plunged 88.37% in 2022.
• A 5-year view of Amortization of Deferred Charges shows it stood at $4.0 million in 2019, then increased by 6.04% to $4.2 million in 2020, then rose by 5.93% to $4.5 million in 2021, then plunged by 88.22% to $530000.0 in 2022, then gained by 0.38% to $532000.0 in 2023.
• Business Quant data shows SUPN's Amortization of Deferred Charges at $532000.0 in Q1 2023, $530000.0 in Q4 2022, and $529000.0 in Q3 2022.